CNS Disorders Preclinical CRO Services
Central nervous system (CNS) disorders are neurological disorders that affect the brain or spinal cord. Nearly 30 million people worldwide are diagnosed with neurological disorders that are caused by aging, injury, infection, cancer, cardiovascular health, metabolism, genetics, environmental exposure, or aging1.
Here at AniLocus, we provide preclinical contract research services for:
Alzheimer’s Disease (AD)
Amyotrophic Lateral Sclerosis (ALS)
Epilepsy & Seizure
Brain Cancer (Chondrosarcoma, Glioblastoma, Medulloblastoma, Meningiomas, Olfactory neuroblastoma)
Cerebrovascular Disease (Stroke)
Huntington’s Disease (HD)
Lewy Body Disease
Pain (Neuropathic, Chronic, Acute)
Parkinson’s Disease (PD)
Rare Neurological Disorders
Spinal Cord Injury (SCI)
Spinal Muscular Atrophy
Traumatic Brain Injury (TBI)
- Learn more: Our Services
How Can AniLocus Help You?
We are experienced in the design and execution of NDA-enabling and IND-enabling preclinical studies for efficacy, safety, in vivo pharmacology, pharmacokinetics (PK), pharmacodynamics (PD), ADME (absorption, distribution, metabolism, and excretion), toxicology, local tolerance–Learn more!
Model Selection for CNS Disorders
Animal models of neurological disorders can be complex because neurological diseases can behave randomly. The preclinical model that you select allows you to perform crucial lead optimization and development steps with:
- Pharmacokinetics/pharmacodynamics (PKPD)
- Safety + toxicology
- In vivo pharmacology
Key Readouts for CNS Disorders
- Immunoassays (ELISA, EIA, Luminex, Immunohistochemistry, In Situ Hybridization)
- Neurological Imaging (MRI, PET, CT, magnetic resonance spectroscopy)
- Neurological Disease-Associated Biomarkers
- Locomotor Activity (Open Field Test, Rotarod)
- Cognition & Memory Behavioral Assays (Novel Object Recognition, Spatial Memory)
- Mood (OFT, Anhedonia Tests, Elevated Plus Maze, Sociability)
- Pain assessments (Weight bearing, von Frey, visceromotor reflex, EMG activity)
- Quantitative Molecular and Cellular Analysis
Drug Modalities for CNS Disorders
- Cellular therapeutics (human-derived iPSCs)
- Gene therapeutics (AAV, CRISPR, TALEN)
- single-stranded antisense oligonucleotides (AON)
- double-stranded small interfering RNA (siRNA) molecules
- Small and large molecule therapeutics
Multiple animal models are used in preclinical research including:
- Gene knockout/knockin/trapped
- Transgenic rodents
- Chemically-Induced Point Mutation rodents
- Stress-induced models
- Drug-Induced models
- Metabolically-induced models (Diet-induced, Metabolic disorder, micronutrient deficient)
- And more…
We conduct translational animal studies (in vivo and in vitro) collecting detailed, comprehensive results with rapid turnaround.
Drug modalities are different types of therapeutic agents. Each drug is a customizable tool designed for therapeutic intervention. The question is…does your product work and is it safe?
At AniLocus, we conduct relevant preclinical studies to assess any drug modality:
- Antibodies (nanobodies, monoclonal)
- Gene therapy (CRISPR, TALEN)
- Viral therapy (adenovirus-AAV, lentivirus)
- Oligo- and polypeptides (e.g., stapled and modified peptides)
- Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
- Macrocyclic molecules
- Drug conjugates (e.g., antibody–drug conjugates, drug–drug conjugates, fluorescence-labeled drugs)
- Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
- Cellular therapies (stem cells, allogenic, autologous)
Using animal and human cells and tissue we can perform multiple interrogative assays depending on therapeutic area and sample type:
- DNA: Extraction, PCR, ddPCR, qPCR, sequencing, genotyping
- RNA: Gene expression profiling, RT-PCR, miRNA, Next-generation sequencing (Nanostring, Illumina), spatial transcriptomics, In situ hybridization (ISH), Multiplex ISH
- Protein: Immunoassays (ELISA, EIA, Luminex), proteomics, ligand binding assays, protein expression, immunohistochemistry (IHC), immunocytochemistry (ICC), and immunofluorescence (IF)
- And more!
- Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., & Murray, C. (2020). The global burden of neurological disorders: translating evidence into policy. The Lancet. Neurology, 19(3), 255–265.
- Li, Z., Ruan, M., Chen, J., & Fang, Y. (2021). Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications. Neuroscience bulletin, 37(6), 863–880.
- Parmar, M., Grealish, S., & Henchcliffe, C. (2020). The future of stem cell therapies for Parkinson disease. Nature reviews. Neuroscience, 21(2), 103–115.
- Spanagel R. Ten Points to Improve Reproducibility and Translation of Animal Research. Front Behav Neurosci. 2022 Apr 21;16:869511. doi: 10.3389/fnbeh.2022.869511. PMID: 35530730; PMCID: PMC9070052.
- Sikora E, Bielak-Zmijewska A, Dudkowska M, Krzystyniak A, Mosieniak G, Wesierska M and Wlodarczyk J (2021) Cellular Senescence in Brain Aging. Front. Aging Neurosci. 13:646924. doi: 10.3389/fnagi.2021.646924.